Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 134 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Furosemide Clear all
Completed Not applicable Interventional Results available

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

NCT05174312
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Reprieve Decongestion Management System, Diuretic
Device · Drug
Lead sponsor
Reprieve Cardiovascular, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Fairhope, Alabama • Irvine, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 17, 2026, 1:35 AM EDT
Terminated Phase 2 Interventional Results available

Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial

NCT03259165
View directory record Official record
Conditions
Heart Failure, Heart Failure Acute, Acute Cardiac Failure, Acute Cardiac Pulmonary Edema
Interventions
Nitrates, Loop Diuretics
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Indianapolis, Indiana • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

Furoscix in Heart Failure Patients With Diuretic Resistance

NCT05528588
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix, Diuretic Therapy
Combination Product · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

Early Diuresis Following Colorectal Surgery

NCT02351934
View directory record Official record
Conditions
Colorectal Disorders
Interventions
Furosemide, Celecoxib, Gabapentin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

NCT04763226
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986308, Placebo (for BMS-986308), Furosemide
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ultra High Dose Diuretics to Treat Heart Failure

NCT06036914
View directory record Official record
Conditions
Heart Failure; With Decompensation
Interventions
Bumetanide, Furosemide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Plasma Osmolality on Brain Glutamate

NCT00611741
View directory record Official record
Conditions
Schizophrenia
Interventions
furosemide, Na supplements
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metformin and Furosemide Drug-Drug Interaction Study

NCT02028689
View directory record Official record
Conditions
Healthy
Interventions
Lesinurad 400 mg, Metformin 850 mg, Furosemide 40 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 17, 2026, 1:35 AM EDT
Terminated Phase 4 Interventional Results available

Outpatient Recovery From Acute Kidney Injury Requiring Dialysis

NCT05158153
View directory record Official record
Conditions
Acute Kidney Injury, Dialysis Hypotension
Interventions
ORKID Bundled Intervention, Furosemide
Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 17, 2026, 1:35 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Salt-Sensitivity and Immunity Cell Activation

NCT03753204
View directory record Official record
Conditions
High Blood Pressure, Salt; Excess, Inflammation
Interventions
Furosemide 40 mg
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 2 Interventional

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

NCT00159614
View directory record Official record
Conditions
Heart Failure, Congestive, Renal Insufficiency
Interventions
KW-3902IV
Drug
Lead sponsor
NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
6
States / cities
San Diego, California • Baltimore, Maryland • Ayer, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Central Sodium Sensing: Implications for Blood Pressure Regulation

NCT05480722
View directory record Official record
Conditions
Salt Sensitivity of Blood Pressure
Interventions
Hypertonic Saline with furosemide, Hypertonic Saline without furosemide
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability

NCT04161482
View directory record Official record
Conditions
Healthy
Interventions
Furosemide 80 mg (8 mg/mL)
Drug
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 17, 2026, 1:35 AM EDT
Recruiting No phase listed Observational

A Study of Paramedic HF Management

NCT06874556
View directory record Official record
Conditions
Heart Failure
Interventions
CP-HF Management
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

NCT03296813
View directory record Official record
Conditions
Heart Failure
Interventions
Torsemide, Furosemide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,973 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
60
States / cities
Alexander City, Alabama • Huntsville, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 17, 2026, 1:35 AM EDT
Recruiting Phase 3 Interventional

Bumetanide vs. Furosemide in Cirrhosis

NCT06941415
View directory record Official record
Conditions
Cirrhosis
Interventions
Bumetanide, Furosemide
Drug
Lead sponsor
Stacy Johnson
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 17, 2026, 1:35 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

NCT05779943
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Furosemide, F18-rhPSMA-7.3, Positron Emission Tomography, Computed Tomography
Drug · Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 17, 2026, 1:35 AM EDT
Withdrawn Phase 3 Interventional

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

NCT07223502
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 1:35 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Clinical Utility of Subcutaneous Furosemide in Patients Presenting With Early Signs of Fluid Overload

NCT03359161
View directory record Official record
Conditions
Heart Failure
Interventions
sc2Wear Furosemide Infusor
Combination Product
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Results available

Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot

NCT02877095
View directory record Official record
Conditions
Acute Heart Failure
Interventions
Furosemide
Drug
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction

NCT01901809
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
Furosemide, Dopamine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Sub-Q Versus IV Furosemide in Acute Heart Failure

NCT02579057
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Furosemide Injection Solution (SCP-101), Furosemide Injection Solution, USP
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 1Phase 2 Interventional

Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

NCT02575963
View directory record Official record
Conditions
AML
Interventions
Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only), Spironolactone
Drug · Biological
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
16
States / cities
Los Angeles, California • Lexington, Kentucky • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 17, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dapagliflozin in Acute Heart Failure

NCT04298229
View directory record Official record
Conditions
Heart Failure, Diabetes Mellitus, Type 2
Interventions
Dapagliflozin 10 MG, Protocolized Diuretic Therapy
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Jackson, Mississippi • Chapel Hill, North Carolina • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 17, 2026, 1:35 AM EDT